Nontuberculous Mycobacterial Ntm Infections Market

DelveInsight’s Nontuberculous Mycobacteria Infection (NTM) - Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Nontuberculous Mycobacteria Infection in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.


The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Nontuberculous Mycobacteria Infection (NTM) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.


Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


The DelveInsight Nontuberculous Mycobacteria Infection (NTM) market report gives the thorough understanding of the Nontuberculous Mycobacteria Infection (NTM) by including details such as disease definition, causes, symptoms, pathophysiology, and diagnostic trends. It also provides overview of treatment and management of the disease in the US, EU5 and Japan. 


Nontuberculous Mycobacterial (NTM) Infections Disease Understanding and Treatment Algorithm

Nontuberculous Mycobacteria Infection (NTM) is caused by nontuberculous mycobacteria which are ubiquitous, aerobic, non-motile, acid-fast bacteria commonly found in soil and water. Inhalation of these bacteria may cause disease in both healthy personnel and those with compromised immune systems.

The report covers the details of conventional and current medical therapies available in the NTM market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithm across the United States, Europe and Japan. 

 


Nontuberculous Mycobacterial (NTM) Infections Epidemiology  

The Nontuberculous Mycobacteria Infection epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool, treatable patient pool and the prevalence based on various parameters such as species type and severity in the US, EU5 and Japan.  


Key Findings


  • According to DelveInsight, the prevalent population of NTM in 7MM is expected to increase at a CAGR of 0.6% for the study period i.e. 2017–2030.


  • United States has the highest number of prevalent cases of NTM infections among all the 7MM countries.


  • According to a study by Wagner et al. (2014), the prevalence of PNTM in Europe ranged from 5.9 per 100,000 in Spain to 6.5 per 100,000 in the UK. 


Country Wise- Nontuberculous Mycobacterial (NTM) Infections Epidemiology 

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, total diagnosed prevalent cases, total treatable population, prevalence based on species, and prevalence based on severity) scenario of Nontuberculous Mycobacteria Infection in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2030. 


Nontuberculous Mycobacterial (NTM) Infections Drug Chapters

This segment of the NTM Drug report encloses the detailed analysis of the emerging drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, and the latest news and press releases.


As majority of clinical manifestations of NTM infections are related to lung infection, the treatment regimen mainly includes the usage of antimycobacterial therapy. Thus, owing to the symptomatic treatment in target patient population, the current therapeutic revenue of NTM infections covered in the report solely focuses on the market revenue generated by antibiotics used for the management of NTM lung infection. These include oral, intravenous as well as inhaled antibiotics.


Marketed Drugs 


Arikayce: Insmed

Arikayce (amikacin) is an aminoglycoside antibacterial indicated in adults who have limited or no alternative treatment options, for the treatment of MAC lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of six consecutive months of a multidrug background regimen therapy.

Products detail in the report…


Nontuberculous Mycobacterial (NTM) Infections Emerging Drugs 


RHB-204: RedHill Biopharma

RHB-204 (Clarithromycin/rifabutin/clofazimine) is a proprietary investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties.

Products detail in the report…


Nontuberculous Mycobacterial (NTM) Infections Market Outlook

The NTM market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers.


This segment gives a through detail of emerging therapies and other promising therapies by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


According to DelveInsight, the market of Nontuberculous Mycobacteria Infection in 7MM was found to be USD 1,815.1 Million in 2017.


Key Findings

This section includes a glimpse of the Nontuberculous Mycobacterial (NTM) Infections market in 7MM.


The United States Market Outlook

This section provides the total Nontuberculous Mycobacterial (NTM) Infections market size and market size by therapies in the United States.


EU-5 Countries: Market Outlook

The total Nontuberculous Mycobacterial (NTM) Infections market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.


Japan Market Outlook 

The total Nontuberculous Mycobacterial (NTM) Infections market size and market size by therapies in Japan is also mentioned. 


Nontuberculous Mycobacterial (NTM) Infections Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Nontuberculous Mycobacterial (NTM) Infections market or expected to get launched in the market during the study period 2017-2030. The analysis covers Nontuberculous Mycobacterial (NTM) Infections market uptake by drugs; patient uptake by therapies; and sales of each drug.    


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Nontuberculous Mycobacterial (NTM) Infections Pipeline Development Activities 

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Nontuberculous Mycobacterial (NTM) Infections key players involved in developing targeted therapeutics. 


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Nontuberculous Mycobacterial (NTM) Infections emerging therapies.


Reimbursement Scenario in Nontuberculous Mycobacterial (NTM) Infections

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy. 


KOL- Views 

To keep up with current market trends, we take KOLs and SME's opinion working in Nontuberculous Mycobacterial (NTM) Infections domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Nontuberculous Mycobacterial (NTM) Infections market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs. 


Competitive Intelligence Analysis 

We perform Competitive and Market Intelligence analysis of the Nontuberculous Mycobacterial (NTM) Infections Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.


Scope of the Report

  • The report covers the descriptive overview of Nontuberculous Mycobacterial (NTM) Infections, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Nontuberculous Mycobacterial (NTM) Infections epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Nontuberculous Mycobacterial (NTM) Infections are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Nontuberculous Mycobacterial (NTM) Infections market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Nontuberculous Mycobacterial (NTM) Infections market


Report Highlights

  • In the coming years, Nontuberculous Mycobacterial (NTM) Infections market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Nontuberculous Mycobacterial (NTM) Infections R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition       
  • Major players are involved in developing therapies for Nontuberculous Mycobacterial (NTM) Infections. Launch of emerging therapies will significantly impact the Nontuberculous Mycobacterial (NTM) Infections market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Nontuberculous Mycobacterial (NTM) Infections
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities


Nontuberculous Mycobacterial (NTM) Infections Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Nontuberculous Mycobacterial (NTM) Infections Pipeline Analysis
  • Nontuberculous Mycobacterial (NTM) Infections Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies


Nontuberculous Mycobacterial (NTM) Infections Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage 
  • Nontuberculous Mycobacterial (NTM) Infections Epidemiology Segmentation
  • Key Cross Competition 
  • Highly Analyzed Market
  • Drugs Uptake


Nontuberculous Mycobacterial (NTM) Infections Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers


Key Questions

Market Insights:

  • What was the Nontuberculous Mycobacterial (NTM) Infections market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Nontuberculous Mycobacterial (NTM) Infections total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Nontuberculous Mycobacterial (NTM) Infections market size during the forecast period (2017-2030)?
  • At what CAGR, the Nontuberculous Mycobacterial (NTM) Infections market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Nontuberculous Mycobacterial (NTM) Infections market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Nontuberculous Mycobacterial (NTM) Infections market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Nontuberculous Mycobacterial (NTM) Infections?
  • What is the historical Nontuberculous Mycobacterial (NTM) Infections patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Nontuberculous Mycobacterial (NTM) Infections in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Nontuberculous Mycobacterial (NTM) Infections?
  • Out of all 7MM countries, which country would have the highest prevalent population of Nontuberculous Mycobacterial (NTM) Infections during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Nontuberculous Mycobacterial (NTM) Infections treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Nontuberculous Mycobacterial (NTM) Infections in the USA, Europe, and Japan?
  • What are the Nontuberculous Mycobacterial (NTM) Infections marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Nontuberculous Mycobacterial (NTM) Infections?
  • How many therapies are developed by each company for Nontuberculous Mycobacterial (NTM) Infections treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Nontuberculous Mycobacterial (NTM) Infections treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Nontuberculous Mycobacterial (NTM) Infections therapies? 
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies? 
  • What are the clinical studies going on for Nontuberculous Mycobacterial (NTM) Infections and their status?
  • What are the key designations that have been granted for the emerging therapies for Nontuberculous Mycobacterial (NTM) Infections?
  • What are the global historical and forecasted market of Nontuberculous Mycobacterial (NTM) Infections?


Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Nontuberculous Mycobacterial (NTM) Infections market
  • To understand the future market competition in the Nontuberculous Mycobacterial (NTM) Infections market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Nontuberculous Mycobacterial (NTM) Infections in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Nontuberculous Mycobacterial (NTM) Infections market
  • To understand the future market competition in the Nontuberculous Mycobacterial (NTM) Infections market


What is Nontuberculous Mycobacteria Infection?

Nontuberculous Mycobacteria Infection is caused by nontuberculous mycobacteria which are ubiquitous, aerobic, non-motile, acid-fast bacteria commonly found in soil and water. Inhalation of these bacteria may cause disease in both healthy personnel and those with compromised immune systems


At what CAGR, Nontuberculous Mycobacteria Infection prevalent population in 7MM is expected to grow for the study period 2017-30?

The prevalent population of Nontuberculous Mycobacteria Infection in 7MM is expected to increase at a CAGR of 0.6% for the study period i.e. 2017–2030


What was the Nontuberculous Mycobacteria Infection market in 2017?

The market of Nontuberculous Mycobacteria Infection in 7MM was found to be USD 1,815.1 Million in 2017


Which geography has the highest Nontuberculous Mycobacteria Infection prevalent cases?

The United States has the highest number of Nontuberculous Mycobacteria Infection prevalent cases among all the 7MM countries


Which companies are developing drugs for Nontuberculous Mycobacteria Infection?

Insmed Incorporated, RedHill Biopharma, Novoteris, Savara Inc, Beyond Air are developing drugs for Nontuberculous Mycobacteria Infection

1. Key Insights

2. Executive Summary

3. Nontuberculous Mycobacteria (NTM) Infections Market Overview At a Glance 

3.1. Market Share (%) Distribution of Nontuberculous Mycobacteria (NTM) Infections in 2017

3.2. Market Share (%) Distribution of Nontuberculous Mycobacteria (NTM) Infections in 2030

4. Nontuberculous Mycobacteria (NTM): Disease Background and Overview

4.1. Introduction

4.2. Causes

4.3. Sign and Symptoms

4.4. Risk Factors

4.5. Common sites of infection

4.6. Pathophysiology

4.7. Diagnosis

4.8. Treatment and Management

5. NTM Patient Journey

6. Case Studies

6.1. United States

6.2. Germany

6.3. France

6.4. Italy

6.5. Spain

6.6. United Kingdom

6.7. Japan

7. Epidemiology and Patient Population

7.1. Epidemiology Key Findings

8. 7MM Total Prevalent Patient Population of Nontuberculous Mycobacteria (NTM) Infections

9. Epidemiology of Nontuberculous Mycobacteria (NTM) Infections

9.1. United States

9.1.1. Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in the United States

9.1.2. Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in the United States

9.1.3. Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) by Species in the United States

9.1.4. Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in the United States

9.1.5. Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in the United States

9.2. EU5

9.2.1. Germany

9.2.2. France

9.2.3. Italy

9.2.4. Spain

9.2.5. The United Kingdom

9.3. Japan

9.3.1. Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Japan

9.3.2. Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Japan

9.3.3. Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) by Species in Japan

9.3.4. Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in Japan

9.3.5. Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in Japan

10. Unmet Needs

11. Organizations contributing towards Nontuberculous Mycobacteria (NTM) Infections

12. KOL Views – Nontuberculous Mycobacteria (NTM) Infections

13. Nontuberculous Mycobacteria (NTM) Infections: 7 Major Market Analysis

13.1. Key Findings

13.2. Market Size of Nontuberculous Mycobacteria (NTM) Infections in 7MM

13.2.1. Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies

14. Market Outlook

15. Marketed Products

15.1. Arikayce: Insmed Incorporated

15.1.1. Product Description

15.1.2. Regulatory Milestones

15.1.3. Safety and Efficacy

15.1.4. Product Profile

16. Emerging Therapies

16.1. Arikayce: Insmed Incorporated

16.1.1. Drug Description

16.1.2. Regulatory Milestones

16.1.3. Clinical Development

16.1.4. Safety and Efficacy

16.1.5. Product Profile

16.2.  RHB-204: RedHill Biopharma

16.2.1. Drug Description

16.2.2. Regulatory Milestones

16.2.3. Clinical Development

16.3.  Thiolanox: Novoteris

16.3.1. Drug Description

16.3.2. Regulatory Milestones

16.3.3. Clinical Development

16.3.4. Safety and Efficacy

16.3.5. Product Profile

16.4.  Molgradex: Savara

16.4.1. Drug Description

16.4.2. Clinical Development

16.4.3. Safety and Efficacy

16.4.4. Product Profile

16.5.  Nitric Oxide: Beyond Air

16.5.1. Drug Description

16.5.2. Regulatory Milestones

16.5.3. Clinical Development

16.5.4. Safety and Efficacy

16.5.5. Product Profile

17. Key Cross Competition

18. United States Market Size

18.1.  Total Market Size of Nontuberculous Mycobacteria (NTM) Infections

18.2.  Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies

19. EU-5 Market Size

19.1.  Germany

19.1.1. Total Market size of Nontuberculous Mycobacteria (NTM) Infections

19.1.2. Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies

19.2.  France

19.2.1. Total Market Size of Nontuberculous Mycobacteria (NTM) Infections

19.2.2. Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies

19.3.  Italy

19.3.1. Total Market Size of Nontuberculous Mycobacteria (NTM) Infections

19.3.2. Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies

19.4. Spain

19.4.1. Total Market Size of Nontuberculous Mycobacteria (NTM) Infections

19.4.2. Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies

19.5. United Kingdom

19.5.1. Total Market Size of Nontuberculous Mycobacteria (NTM) Infections

19.5.2. Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies

20. Japan: Market Size

20.1.1. Total Market Size of Nontuberculous Mycobacteria (NTM) Infections

20.1.2. Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies

21. Market Access and Reimbursement Overview of NTM

21.1. Potential market access hurdles for Arikayce

22. Market Drivers

23. Market Barriers

24. Appendix

24.1. Bibliography

24.2. Report Methodology

25. DelveInsight Capabilities

26. Disclaimer

27. About DelveInsight

*The table of contents is not exhaustive; the final content may vary. 

Table 1 : Demographics and sample sites of patients with less common nontuberculous mycobacteria species

Table 2 : Clinical risk factors and outcomes of patients with isolation of non– Mycobacterium avium complex, non–Mycobacterium gordonae nontuberculous mycobacteria by site of isolation

Table 3 : Clinical risk factors and outcomes in patients who met American Thoracic Society criteria for nontuberculous mycobacterial lung disease (not including patients with Mycobacterium avium complex) in comparison to those with isolation of Mycobacterium gordonae

Table 4 : Primary and acquired immune deficiencies associated with disseminated NTM infection

Table 5 : Treatment recommendations for slowly growing NTM

Table 6 : Common Side Effects and Toxicities of Drugs Used For Therapy or Prophylaxis of Nontuberculous Mycobacterial Disease

Table 7 : Treatment recommendations for rapidly growing NTM

Table 8 : Prevalent Patient Population of Nontuberculous Mycobacteria (NTM) Infections in 7MM (2017–2030)

Table 9 : Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in the United States (2017–2030)

Table 10 : Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in the United States (2017–2030)

Table 11 : Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) by Species in the United States (2017–2030)

Table 12 : Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in the United States (2017–2030)

Table 13 : Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in the United States (2017–2030)

Table 14 : Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Germany (2017–2030)

Table 15 : Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Germany (2017–2030)

Table 16 : Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) by Species in Germany (2017–2030)

Table 17 : Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in Germany (2017–2030)

Table 18 : Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in Germany (2017–2030)

Table 19 : Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in France (2017–2030)

Table 20 : Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in France (2017–2030)

Table 21 : Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) by Species in France (2017–2030)

Table 22 : Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in France (2017–2030)

Table 23 : Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in France (2017–2030)

Table 24 : Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Italy (2017–2030)

Table 25 : Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Italy (2017–2030)

Table 26 : Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) by Species in Italy (2017–2030)

Table 27 : Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in Italy (2017–2030)

Table 28 : Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in Italy (2017–2030)

Table 29 : Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Spain (2017–2030)

Table 30 : Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Spain (2017–2030)

Table 31 : Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) by Species in Spain (2017–2030)

Table 32 : Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in Spain (2017–2030)

Table 33 : Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in Spain (2017–2030)

Table 34 : Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in the United Kingdom (2017–2030)

Table 35 : Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in the United Kingdom (2017–2030)

Table 36 : Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) by Species in the UK (2017–2030)

Table 37 : Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in the UK (2017–2030)

Table 38 : Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in the UK (2017–2030)

Table 39 : Total Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Japan (2017–2030)

Table 40 : Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections in Japan (2017–2030)

Table 41 : Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) by Species in Japan (2017–2030)

Table 42 : Treatable Population of Nontuberculous Mycobacteria (NTM) Infections in Japan (2017–2030)

Table 43 : Diagnosed Prevalent Cases of Nontuberculous Mycobacteria (NTM) Infections by Severity in Japan (2017–2030)

Table 44 : Organizations contributing towards Nontuberculous Mycobacteria (NTM) Infections

Table 45 : 7 Major Market Size of Nontuberculous Mycobacteria (NTM) Infections in USD Million (2017–2030)

Table 46 : 7 Major Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies in USD Million (2017–2030)

Table 47 : Arikayce, Clinical Trial Description, 2019

Table 48 : Thiolanox, Clinical Trial Description, 2019

Table 49 : Molgradex, Clinical Trial Description, 2019

Table 50 : Nitric Oxide, Clinical Trial Description, 2019

Table 51 : Key Cross Competition

Table 52 : United States Market Size of Nontuberculous Mycobacteria (NTM) Infections in USD Million (2017–2030)

Table 53 : US Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies in USD Million (2017–2030)

Table 54 : Germany Market Size of Nontuberculous Mycobacteria (NTM) Infections in USD Million (2017–2030)

Table 55 : Germany Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies in USD Million (2017–2030)

Table 56 : France Market Size of Nontuberculous Mycobacteria (NTM) Infections in USD Million (2017–2030)

Table 57 : France Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies in USD Million (2017–2030)

Table 58 : Italy Market Size of Nontuberculous Mycobacteria (NTM) Infections in USD Million (2017–2030)

Table 59 : Italy Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies in USD Million (2017–2030)

Table 60 : Spain Market Size of Nontuberculous Mycobacteria (NTM) Infections in USD Million (2017–2030)

Table 61 : Spain Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies in USD Million (2017–2030)

Table 62 : United Kingdom Market Size of Nontuberculous Mycobacteria (NTM) Infections in USD Million (2017–2030)

Table 63 : United Kingdom Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies in USD Million (2017–2030)

Table 64 : Japan Market Size of Nontuberculous Mycobacteria (NTM) Infections in USD Million (2017–2030)

Table 65 : Japan Market Size of Nontuberculous Mycobacteria (NTM) Infections by Therapies in USD Million (2017–2030)

Figure 1 : 7MM Nontuberculous Mycobacterial (NTM) Infections Epidemiology (2017-2030)

Figure 2 : 7MM Nontuberculous Mycobacterial (NTM) Infections Diagnosed and Treatable Cases (2017-2030)

Figure 3 : Nontuberculous Mycobacterial (NTM) Infections Epidemiology in the United States (2017-2030)

Figure 4 : Nontuberculous Mycobacterial (NTM) Infections Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 : Nontuberculous Mycobacterial (NTM) Infections Epidemiology in Germany (2017-2030)

Figure 6 : Nontuberculous Mycobacterial (NTM) Infections Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 : Nontuberculous Mycobacterial (NTM) Infections Epidemiology in France (2017-2030)

Figure 8 : Nontuberculous Mycobacterial (NTM) Infections Diagnosed and Treatable Cases in France (2017-2030) 

Figure 9 : Nontuberculous Mycobacterial (NTM) Infections Epidemiology in Italy (2017-2030)

Figure 10 : Nontuberculous Mycobacterial (NTM) Infections Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 : Nontuberculous Mycobacterial (NTM) Infections Epidemiology in Spain (2017-2030)

Figure 12 : Nontuberculous Mycobacterial (NTM) Infections Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 : Nontuberculous Mycobacterial (NTM) Infections Epidemiology in the UK (2017-2030)

Figure 14 : Nontuberculous Mycobacterial (NTM) Infections Diagnosed and Treatable Cases in the UK (2017-2030)

Figure 15 : Nontuberculous Mycobacterial (NTM) Infections Epidemiology in Japan (2017-2030)

Figure 16 : Nontuberculous Mycobacterial (NTM) Infections Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 17 : Drug Name, Clinical Trials by Recruitment status

Figure 18 : Drug Name, Clinical Trials by Zone

Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)

Figure 20 : Region-wise Market Size in USD, Million (2017-2030)

Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)

Figure 22 : United States Market Size in USD, Million (2017-2030)

Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)

Figure 24 : Germany Market Size in USD, Million (2017-2030)

Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)

Figure 26 : France Market Size in USD, Million (2017-2030)

Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)

Figure 28 : Italy Market Size in USD, Million (2017-2030)

Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)

Figure 30 : Spain Market Size in USD, Million (2017-2030)

Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)

Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)

Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)

Figure 34 : Japan Market Size in USD, Million (2017-2030)

Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

*The list of figures is not exhaustive; the final content may vary.

  • Tags:
  • Nontuberculous Mycobacterial (NTM)...
  • Nontuberculous Mycobacterial (NTM)...
  • Nontuberculous Mycobacterial (NTM)...
  • Nontuberculous Mycobacterial (NTM)...
  • Nontuberculous Mycobacterial (NTM)...
  • Nontuberculous Mycobacterial (NTM)...
  • Nontuberculous Mycobacterial (NTM)...
  • Nontuberculous Mycobacterial (NTM)...
  • Nontuberculous Mycobacterial (NTM)...
  • Nontuberculous Mycobacterial (NTM)...
  • Nontuberculous Mycobacterial (NTM)...
  • Nontuberculous Mycobacterial (NTM)...
  • Nontuberculous Mycobacterial (NTM)...
  • Nontuberculous Mycobacterial (NTM)...

Forward to Friend

Need A Quote